First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context.

Rajput, Rajesh; Ghosh, Sujoy; Banerjee, Samar; Bansal, Beena; Chawla, Manoj; Ahluwalia, Abhay I; Lathia, Tejal; Das, Ashok K

Rajput, Rajesh; Ghosh, Sujoy; Banerjee, Samar; Bansal, Beena; Chawla, Manoj; Ahluwalia, Abhay I; Lathia, Tejal; Das, Ashok K.

Afiliación

Rajput R; Department of Endocrinology, PGIMS, Rohtak, Haryana, India.
Ghosh S; Department of Endocrinology, IPGME&R, Kolkata, West Bengal, India.
Banerjee S; Department of Medicine, Vivekananda Institute of Medical Sciences, Kolkata, West Bengal, India.
Bansal B; Consultant, Department of Endocrinologist, Door-To-Care, An Endocrine and Diabetes Clinic, Gurugram, Haryana, India.
Chawla M; MBBS, Diabetologist, FRSSDI, FRCP (Edin), Director and Consultant Diabetologist, Lina Diabetes Care Centre, Mumbai, Maharashtra, India.
Ahluwalia AI; Senior Consultant, Department of Endocrinologist Manipal Hospital, Gurgaon, Haryana, India.
Lathia T; Consultant, Department of Endocrinologist, Fortis, Apollo and Cloud Nine Hospitals, Navi Mumbai, Maharashtra, India.
Das AK; Consultant, Department of Endocrinologist, Pondicherry Institute of Medical Sciences, Kalapet, Puducherry, India.

Indian J Endocrinol Metab ; 26(5): 417-427, 2022.

Article en En | MEDLINE | ID: mdl-36618518

Palabras clave

First-in-class; India; glucagon-like peptide-1 receptor agonists; innovation; oral semaglutide; type 2 diabetes mellites

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Indian J Endocrinol Metab Año: 2022 Tipo del documento: Article País de afiliación: India

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google